Company: RITM-PC
Filing Date: 2025-09-19
Form Type: 424B5
Source: 0001140361-25-035596
Chunk: 64

Company: Rithm Capital Corp.
Filing Date: 2025-09-19
Form: 424B5
Chunk 64
---
 by the underwriters’ option to purchase additional shares of the Series E Preferred Stock described below. The Series E Preferred Stock is offered subject to a number of conditions, including:

| • | receipt and acceptance of the Series E Preferred Stock by the underwriters; and |

| • | the underwriters’ right to reject orders in whole or in part. |

In connection with this offering, the underwriters may distribute prospectuses electronically. The underwriters initially propose to offer the shares of Series E Preferred Stock directly to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers at a price that represents a concession not in excess of $0.50 per share of Series E Preferred Stock below the public offering price. Any underwriters may allow, and such dealers may re-allow, a concession not in excess of $0.45 per share of Series E Preferred Stock to other underwriters or to certain dealers. If the shares of Series E Preferred Stock are not sold at the initial price to the public, the underwriters may change the offering price and the other selling terms. The offering of the shares of Series E Preferred Stock by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part. We have granted to the underwriters an option to purchase additional shares of Series E Preferred Stock solely to cover over-allotments, exercisable for 30 days from the date of this prospectus supplement, to purchase up to 1,140,000 additional shares of the Series E Preferred Stock at the public offering price less the underwriting discount set forth on the cover page of this prospectus supplement. Our expenses in connection with the offering are estimated at approximately $300,000 and are payable by us. We have agreed that, subject to specified exceptions, without the prior written consent of Morgan Stanley & Co. LLC, we will not, directly or indirectly (a) offer for sale, sell, pledge, enter into any swap or other derivatives transaction that transfers to another any of the economic benefits or risks of ownership of the Series E Preferred Stock, or otherwise dispose of any shares of the Series E Preferred Stock or any securities that may be converted into or exchanged for any shares of the Series E Preferred Stock or (b) file a registration statement under the Securities

S-37

TABLE OF CONTENTS

Act of 1933, as amended (the “Securities Act”) registering shares of the Series E Preferred Stock (or